GlaxoSmithKline plc (LSE/NYSE: GSK) Announced that the US Food and Drug Administration (FDA) has approved Tanzeum (algiblutied) for subcutaneous injection use, as a ounce a week treatment for diabetes type 2. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with diabetes mellitus.
Albiglutide is a glucagon-like peptide-1 receptor agonist and is a biological product to be used once a week using a injection pen with 5mm 29-gauge thin-walled needle. Albiglutide improves the important incretin hormone which is often reduced or absent in diabetics type 2 . Tanzeum is not recommended as a first-line therapy for patients with inadequately controlled diabetes. Tanzeum has not been studied in patients with a history of pancreatitis.
Tanzeum is not for treatment of type 1 diabetes mellitus or diabetes ketoacidosis. Tanzeum has not been studied in patients with pre-existing severe gastrointestinal disease and has not been studied in combination with prandial insulin. Tanzeum has been studied as a stand-alone therapy and in combination with other type 2 diabetes therapies, including metformin, glimepriride, pioglitazone.
Image credit: flickr.com